224 related articles for article (PubMed ID: 12499252)
1. Induction of glioblastoma apoptosis using neural stem cell-mediated delivery of tumor necrosis factor-related apoptosis-inducing ligand.
Ehtesham M; Kabos P; Gutierrez MA; Chung NH; Griffith TS; Black KL; Yu JS
Cancer Res; 2002 Dec; 62(24):7170-4. PubMed ID: 12499252
[TBL] [Abstract][Full Text] [Related]
2. Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression.
Shah K; Bureau E; Kim DE; Yang K; Tang Y; Weissleder R; Breakefield XO
Ann Neurol; 2005 Jan; 57(1):34-41. PubMed ID: 15622535
[TBL] [Abstract][Full Text] [Related]
3. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.
Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J
Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708
[TBL] [Abstract][Full Text] [Related]
4. The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma.
Ehtesham M; Kabos P; Kabosova A; Neuman T; Black KL; Yu JS
Cancer Res; 2002 Oct; 62(20):5657-63. PubMed ID: 12384520
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas.
Corsten MF; Miranda R; Kasmieh R; Krichevsky AM; Weissleder R; Shah K
Cancer Res; 2007 Oct; 67(19):8994-9000. PubMed ID: 17908999
[TBL] [Abstract][Full Text] [Related]
6. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma.
Kim SM; Lim JY; Park SI; Jeong CH; Oh JH; Jeong M; Oh W; Park SH; Sung YC; Jeun SS
Cancer Res; 2008 Dec; 68(23):9614-23. PubMed ID: 19047138
[TBL] [Abstract][Full Text] [Related]
7. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas.
Nakamizo A; Marini F; Amano T; Khan A; Studeny M; Gumin J; Chen J; Hentschel S; Vecil G; Dembinski J; Andreeff M; Lang FF
Cancer Res; 2005 Apr; 65(8):3307-18. PubMed ID: 15833864
[TBL] [Abstract][Full Text] [Related]
8. Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity.
Roth W; Isenmann S; Naumann U; Kügler S; Bähr M; Dichgans J; Ashkenazi A; Weller M
Biochem Biophys Res Commun; 1999 Nov; 265(2):479-83. PubMed ID: 10558893
[TBL] [Abstract][Full Text] [Related]
9. Complete elimination of colorectal tumor xenograft by combined manganese superoxide dismutase with tumor necrosis factor-related apoptosis-inducing ligand gene virotherapy.
Zhang Y; Gu J; Zhao L; He L; Qian W; Wang J; Wang Y; Qian Q; Qian C; Wu J; Liu XY
Cancer Res; 2006 Apr; 66(8):4291-8. PubMed ID: 16618754
[TBL] [Abstract][Full Text] [Related]
10. Effect of human skin-derived stem cells on vessel architecture, tumor growth, and tumor invasion in brain tumor animal models.
Pisati F; Belicchi M; Acerbi F; Marchesi C; Giussani C; Gavina M; Javerzat S; Hagedorn M; Carrabba G; Lucini V; Gaini SM; Bresolin N; Bello L; Bikfalvi A; Torrente Y
Cancer Res; 2007 Apr; 67(7):3054-63. PubMed ID: 17409412
[TBL] [Abstract][Full Text] [Related]
11. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
[TBL] [Abstract][Full Text] [Related]
12. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.
Hyer ML; Croxton R; Krajewska M; Krajewski S; Kress CL; Lu M; Suh N; Sporn MB; Cryns VL; Zapata JM; Reed JC
Cancer Res; 2005 Jun; 65(11):4799-808. PubMed ID: 15930300
[TBL] [Abstract][Full Text] [Related]
13. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.
Jin H; Yang R; Fong S; Totpal K; Lawrence D; Zheng Z; Ross J; Koeppen H; Schwall R; Ashkenazi A
Cancer Res; 2004 Jul; 64(14):4900-5. PubMed ID: 15256461
[TBL] [Abstract][Full Text] [Related]
14. Cancer gene therapy using a novel secretable trimeric TRAIL.
Kim CY; Jeong M; Mushiake H; Kim BM; Kim WB; Ko JP; Kim MH; Kim M; Kim TH; Robbins PD; Billiar TR; Seol DW
Gene Ther; 2006 Feb; 13(4):330-8. PubMed ID: 16195699
[TBL] [Abstract][Full Text] [Related]
15. Neural progenitor cell lines inhibit rat tumor growth in vivo.
Staflin K; Honeth G; Kalliomäki S; Kjellman C; Edvardsen K; Lindvall M
Cancer Res; 2004 Aug; 64(15):5347-54. PubMed ID: 15289341
[TBL] [Abstract][Full Text] [Related]
16. Search and destroy: recent research exploits adult stem cells' attraction to cancer.
Brower V
J Natl Cancer Inst; 2005 Mar; 97(6):414-6. PubMed ID: 15770001
[No Abstract] [Full Text] [Related]
17. Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy.
Menon LG; Kelly K; Yang HW; Kim SK; Black PM; Carroll RS
Stem Cells; 2009 Sep; 27(9):2320-30. PubMed ID: 19544410
[TBL] [Abstract][Full Text] [Related]
18. Enhanced apoptosis of glioma cell lines is achieved by co-delivering FasL-GFP and TRAIL with a complex Ad5 vector.
Rubinchik S; Yu H; Woraratanadharm J; Voelkel-Johnson C; Norris JS; Dong JY
Cancer Gene Ther; 2003 Nov; 10(11):814-22. PubMed ID: 14605667
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells.
Earel JK; VanOosten RL; Griffith TS
Cancer Res; 2006 Jan; 66(1):499-507. PubMed ID: 16397266
[TBL] [Abstract][Full Text] [Related]
20. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice.
Pei Z; Chu L; Zou W; Zhang Z; Qiu S; Qi R; Gu J; Qian C; Liu X
Hepatology; 2004 May; 39(5):1371-81. PubMed ID: 15122766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
